Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Pilot Study Validates RAD Terbium-161 Radiotherapeutics

Wednesday, February 28, 2024 1 min read
Key Takeaway: The pilot study has successfully validated RAD Terbium-161 radiotherapeutics, indicating promising results for future clinical applications. This development enhances the credibility of the technology and may lead to further advancements in the field of radiopharmaceuticals. The positive outcomes from this study could significantly impact treatment options for patients.

Market Sentiment Analysis

POSITIVE FACTORS

  • Successful validation of RAD Terbium-161 radiotherapeutics.
  • Positive implications for future clinical applications.
  • Strengthens the company's position in radiopharmaceuticals.

Full Press Release Details

• Announcements
• Price Sensitive
• February 28, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• March 17, 2025
• Announcements
• July 8, 2024
• Announcements
• December 20, 2024
• Announcements
• October 19, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What was validated in the pilot study?

The pilot study successfully validated RAD Terbium-161 radiotherapeutics.

What are the implications of the study's results?

The results indicate promising prospects for future clinical applications.

Tags: RADX Viatris Investor Conferences Healthcare radiopharmaceuticals clinical study Terbium-161 radiotherapeutics
Last updated: Feb 28, 2024